Biologics

IONTAS and FairJourney Biologics (FJB) have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. A diverse panel of novel target binders from IONTAS and FairJourney Biologics (FJB) will be used to identify antibodies to advance Quell’s engineered Treg cell therapy pipeline. Quell harnesses the suppressive capacity of […]

Samsung Biologics has obtained Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). […]

Michael Smyth is Medical Director at Galapagos UK, responsible for launching innovative therapies in the UK to help change the course of inflammatory disease for patients. Having studied medicine at Liverpool University, one of his personal missions is lifelong learning which is reflected in his role to strive for new treatment options that lead to better […]

Solentim, expert in cell therapy workflows enabling the creation, isolation and characterisation of high value cells, has launched two solutions to enhance the development of therapeutic antibodies. Icon is a benchtop system for the rapid stratification of high productivity clones and Studius is a proprietary software platform that delivers data on each cell’s journey through […]

Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase expansion of its plasmid DNA services, a continuation of its gene therapy services’ project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ High Quality (HQ) DNA manufacturing capacity alongside new clinical and commercial GMP DNA […]

Leukocare, a German biotechnology company specialising in formulation development for biologics, viral vectors and vaccines, has opened development labs in Milford, USA. Its headquarters will remain in Martinsried/Munich, Germany. Being present in the US market offers the opportunity to collaborate closely with customers and partners on tailor-made solutions in the field of drug product formulation […]

Dr Elizabeth Fairley, COO and co-founder of social intelligence company Talking Medicines, explains how technology has shaped the drug landscape and why actually listening to patients might be the breakthrough the industry needs. There are more drugs on the market today than ever before and the drug pipeline is massively more accelerated than it was […]

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the lives of more than 9 […]

Carterra, specialist in label-free high throughput antibody screening and characterisation, has closed on a round of equity financing led by PerkinElmer. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round. The Carterra LSA platform for accelerating the discovery of therapeutic antibodies has become a standard in many of […]

IDBS has launched Polar biopharma lifecycle management (BPLM),  which is aimed at streamlining drug development and manufacturing in biopharma research. The development of biologics is a dynamic process and those who are most successful must be able to adapt to changes in process or technology rapidly. IDBS data has found that without effective BPLM, the […]